ObesityNCT05309057
Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk
An observational study of Obesity and PreDiabetes, run by University of Toronto at 2 sites in Canada.
Trial summary
Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Obesity, PreDiabetes, Diabetes
- What is being tested?
- Intermittent Fasting
- How many people
- 25 participants
- Where
- 2 sitesCanada
- Study dates
- 1 Nov 2020to Aug 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Adults of all health statuses.
Who may be able to join
- Randomized controlled trials in humans
- Intermittent fasting intervention
- Continuous energy restriction, ad libitum diet, or other intermittent fasting diet as comparators
- Diet duration ≥1 weeks
- Data for at least one prespecified outcome
- Viable outcome data
Who cannot join
- Non-human studies
- Observational studies
- Children
- Multi-modal interventions
- Diet duration < 1 weeks
- No viable outcome data
- Lack of suitable comparator
Trial locations and contacts
2 sites in 1 country.
Canada2 sites
Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital
Toronto, Ontario, M5C 2T2
Faculty of Medicine
Toronto, Ontario
About this study
Official title: Effect of Intermittent Fasting Strategies on Cardiometabolic Risk: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. There is emerging evidence that intermittent fasting or energy restriction might be more beneficial than continuous energy restriction for some risk factors. The effect of intermittent fasting on risk factors associated with obesity, diabetes, and cardiovascular disease, however, is not clear. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, tthe Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis of randomized controlled trials of the effect of different intermittent fasting strategies on established cardiometabolic risk factors. The findings generated by this proposed knowledge synthesis will shape guide current guidelines and improve health outcomes by educating healthcare providers and patients, and by guiding future research design.
Read the detailed description
Background: 'Intermittent fasting' is currently the most popular trending diet, yet its clinical utility remains unclear. Previous systematic reviews and meta-analyses of intermittent fasting have been limited by a narrow focus on weight loss, one specific method of intermittent fasting, and/or a subset of participants who would be the least likely to benefit. Other issues have included unexplained heterogeneity, incorrect analyses and/or lack of assessment of the certainty of the evidence. There is emerging evidence that intermittent fasting may improve cardiometabolic risk markers independent of calories. However, there is a lack of certainty about the effectiveness of intermittent fasting on overall cardiometabolic risk across different health conditions, and the differences between the various methods of intermittent fasting. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, the Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis (an approach which has the advantage over traditional pairwise meta-analyses of being able to assess simultaneously multiple interventions) to assess the effect of the different strategies of intermittent energy restriction (intermittent fasting) versus continuous energy restriction and ad libitum diets on cardiometabolic risk in randomized controlled trials and assess the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Objective: To assess simultaneously the effect of the various strategies of intermittent energy restriction (intermittent fasting), continuous energy restriction, and ad libitum diets on body weight and other cardiometabolic risk factors in a systematic review and network meta-analysis of randomized trials using the GRADE approach.
Design: Each systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for network meta-analyses (PRISMA-Network).
Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms. These searches will be supplemented by hand searches of references of included studies. Abstracts will be included and no language restrictions will be used.
Study selection: The investigators will include randomized controlled trials (RCTs) that are >=3-weeks duration investigating the effect of intermittent fasting, continuous caloric restriction and/or ad libitum diets on cardiometabolic risk factors in adults.
Data extraction: Two or more investigators will independently extract relevant data. Standard computations and imputations will be used to derive missing variance data. All disagreements will be resolved by consensus.
Risk of bias: Risk of bias will be assessed using the Cochrane Risk of Bias (RoB) Tool by the two or more investigators.
Outcomes: There will be 10 outcome clusters. The primary outcome will be body weight. Secondary outcomes will be other markers of adiposity (BMI, body fat, waist circumference); glycemic control (glycated blood proteins [HbA1c, fasting blood glucose, postprandial blood glucose, fasting blood insulin, homeostasis model assessment of insulin resistance [HOMA-IR]); established therapeutic lipid targets (LDL-cholesterol, non-HDL-cholesterol, apolipoprotein B [apo B], HDL-cholesterol, triglycerides); blood pressure (systolic blood pressure and diastolic blood pressure); markers of NAFLD (intrahepatocellular lipids [IHCL], alanine aminotransferase [ALT], aspartate aminotransferase [AST]); uric acid; and markers of inflammation (CRP).
Data synthesis: The investigators will perform a network meta-analysis comparing all the interventions simultaneously. These interventions will include alternate day fasting, cyclical whole day fasting, time restricted feeding, continuous energy restriction, and ad libitum diet in a single analysis by combining both direct and indirect evidence across the selected network of studies. Separate pooled analyses will be conducted for each cardiometabolic risk factor using the random-effects network meta-analysis. Intrasitivity will be adjudged using incoherence. Global method of incoherence (design-by-treatment interaction) and inconsistency factors (disagreement between direct and indirect estimates) will be used to estimate incoherence. A-priori subgroup analyses (health status, age, control diet energy restriction, diet supervision, study design, follow-up, feeding control, randomization, energy balance, baseline body weight, funding source, and ROB) will be performed. Separate analysis will be performed in people with diabetes. Publication bias will be assessed if there are ≥10 comparisons. The overall certainty of the evidence for each outcome will be assessed with GRADE using the CINeMA approach.
Evidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant decision makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.
Significance: The proposed project will be the most comprehensive synthesis and evaluation of the totality of evidence on the role of intermittent fasting in cardiometabolic health. These findings will aid in strengthening current guidelines and improve health outcomes by informing shared clinical decision making between healthcare providers and patients and guiding future research.
- Conditions
- Obesity, PreDiabetes, Diabetes, Hypertension, NAFLD, Metabolic Syndrome
- Being tested
- Intermittent Fasting
- Keywords
- Intermittent fasting, Continuous energy restriction, Weight loss, Systematic review and meta-analysis, Network metanalysis, Randomized controlled trial, Clinical practice guideline, Adiposity, Glycemic control, Blood pressure, Blood lipids, NAFLD markers, Uric acid, inflammatory markers, Cardiometabolic risk factors
- Medical subject headings
- Obesity, Prediabetic State, Diabetes Mellitus, Hypertension, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Dyslipidemias, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intermittent FastingDietary supplement
Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
| Study group | Role | What they receive |
|---|---|---|
| Studies with intermittent fasting | Studies with intermittent fasting strategies. Receives: Dietary Supplement: Intermittent Fasting |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body weight
Body weight in kg
Measured: Through study completion, up to 20 years
Secondary outcomes (19)
Adiposity - BMI
Body mass index (BMI) in kg/m2
Measured: Through study completion, up to 20 years
Adiposity - Waist circumference
Waist circumference in cm
Measured: Through study completion, up to 20 years
Adiposity - Body fat
Body fat in % (relative units)
Measured: Through study completion, up to 20 years
Glycemic control - HbA1c
Glycemic control - HbA1c
Measured: Through study completion, up to 20 years
Glycemic control - fasting plasma glucose (FPG)
Fasting plasma glucose (FPG) in mmol/L
Measured: Through study completion, up to 20 years
Glycemic control - 2h plasma glucose (2h-PG)
2h plasma glucose (2h-PG) during a 75g oral glucose tolerance test (OGTT) in mmol/L
Measured: Through study completion, up to 20 years
Glycemic control - fasting plasma insulin (FPI)
Fasting plasma insulin (FPI) in pmol/L
Measured: Through study completion, up to 20 years
Glycemic control - homeostasis model assessment of insulin resistance (HOMA-IR)
Homeostasis model assessment of insulin resistance (HOMA-IR)
Measured: Through study completion, up to 20 years
Established blood lipid targets - LDL-cholesterol (LDL-C)
LDL-cholesterol (LDL-C) in mmol/L
Measured: Through study completion, up to 20 years
Established blood lipid targets - non-HDL-cholesterol (non-HDL-C)
non-HDL-cholesterol (non-HDL-C) in mmol/L
Measured: Through study completion, up to 20 years
Established blood lipid targets - apolipoprotein B (apo B)
Apolipoprotein B (apo B) in g/L
Measured: Through study completion, up to 20 years
Established blood lipid targets - triglycerides
Triglycerides in mmol/L
Measured: Through study completion, up to 20 years
Established blood lipid targets - HDL-cholesterol (HDL-C)
HDL-cholesterol (HDL-C) in mmol/L
Measured: Through study completion, up to 20 years
Blood pressure - Systolic blood pressure (SBP)
Systolic blood pressure (SBP) in mmHg
Measured: Through study completion
Blood pressure - diastolic blood pressure (DBP)
Diastolic blood pressure (DBP) in mmHg
Measured: Through study completion, up to 20 years
Markers of non-alcoholic fatty liver disease (NAFLD) - Intrahepatocellular lipids (IHCL)
Intrahepatocellular lipids (IHCL) in % (relative units)
Measured: Through study completion, up to 20 years
Markers of non-alcoholic fatty liver disease (NAFLD) - alanine transaminase (ALT)
Alanine transaminase (ALT) in U/L
Measured: Through study completion, up to 20 years
Uric acid
Uric acid in mmol/L
Measured: Through study completion, up to 20 years
Markers of inflammation - CRP
CRP in mg/dL
Measured: Through study completion, up to 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2022
- Study start1 Nov 2020
- Primary completionJun 2022 (estimated)
- Study completionAug 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by University of TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, John Sievenpiper, University of Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05309057
- Sponsor's protocol ID
- DNSG-IF
- Status last verified
- Mar 2022
- First submitted
- 16 Mar 2022
- Last updated
- 4 Apr 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Semnani-Azad Z, Khan TA, Chiavaroli L, Chen V, Bhatt HA, Chen A, Chiang N, Oguntala J, Kabisch S, Lau DC, Wharton S, Sharma AM, Harris L, Leiter LA, Hill JO, Hu FB, Lean ME, Kahleova H, Rahelic D, Salas-Salvado J, Kendall CW, Sievenpiper JL. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025 Jun 18;389:e082007. doi: 10.1136/bmj-2024-082007.
PubMed 40533200
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Intermittent Fasting Strategies on Cardiometabolic Risk: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
- ClinicalTrials.gov ID
- NCT05309057
- Acronym / sponsor ID
- DNSG-IF
- Conditions
- Obesity, PreDiabetes, Diabetes, Hypertension, NAFLD, Metabolic Syndrome
- Keywords
- Intermittent fasting, Continuous energy restriction, Weight loss, Systematic review and meta-analysis, Network metanalysis, Randomized controlled trial, Clinical practice guideline, Adiposity
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- University of TorontoUniversity, hospital or other
- Study start
- 1 Nov 2020 (actual)
- Primary completion
- Jun 2022 (estimated)
- Study completion
- Aug 2022 (estimated)
- First posted
- 4 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. There is emerging evidence that intermittent fasting or energy restriction might be more beneficial than continuous energy restriction for some risk factors. The effect of intermittent fasting on risk factors associated with obesity, diabetes, and cardiovascular disease, however, is not clear. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, tthe Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis of randomized controlled trials of the effect of different intermittent fasting strategies on established cardiometabolic risk factors. The findings generated by this proposed knowledge synthesis will shape guide current guidelines and improve health outcomes by educating healthcare providers and patients, and by guiding future research design.
Detailed description
Background: 'Intermittent fasting' is currently the most popular trending diet, yet its clinical utility remains unclear. Previous systematic reviews and meta-analyses of intermittent fasting have been limited by a narrow focus on weight loss, one specific method of intermittent fasting, and/or a subset of participants who would be the least likely to benefit. Other issues have included unexplained heterogeneity, incorrect analyses and/or lack of assessment of the certainty of the evidence. There is emerging evidence that intermittent fasting may improve cardiometabolic risk markers independent of calories. However, there is a lack of certainty about the effectiveness of intermittent fasting on overall cardiometabolic risk across different health conditions, and the differences between the various methods of intermittent fasting. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, the Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis (an approach which has the advantage over traditional pairwise meta-analyses of being able to assess simultaneously multiple interventions) to assess the effect of the different strategies of intermittent energy restriction (intermittent fasting) versus continuous energy restriction and ad libitum diets on cardiometabolic risk in randomized controlled trials and assess the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Objective: To assess simultaneously the effect of the various strategies of intermittent energy restriction (intermittent fasting), continuous energy restriction, and ad libitum diets on body weight and other cardiometabolic risk factors in a systematic review and network meta-analysis of randomized trials using the GRADE approach.
Design: Each systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for network meta-analyses (PRISMA-Network).
Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms. These searches will be supplemented by hand searches of references of included studies. Abstracts will be included and no language restrictions will be used.
Study selection: The investigators will include randomized controlled trials (RCTs) that are >=3-weeks duration investigating the effect of intermittent fasting, continuous caloric restriction and/or ad libitum diets on cardiometabolic risk factors in adults.
Data extraction: Two or more investigators will independently extract relevant data. Standard computations and imputations will be used to derive missing variance data. All disagreements will be resolved by consensus.
Risk of bias: Risk of bias will be assessed using the Cochrane Risk of Bias (RoB) Tool by the two or more investigators.
Outcomes: There will be 10 outcome clusters. The primary outcome will be body weight. Secondary outcomes will be other markers of adiposity (BMI, body fat, waist circumference); glycemic control (glycated blood proteins [HbA1c, fasting blood glucose, postprandial blood glucose, fasting blood insulin, homeostasis model assessment of insulin resistance [HOMA-IR]); established therapeutic lipid targets (LDL-cholesterol, non-HDL-cholesterol, apolipoprotein B [apo B], HDL-cholesterol, triglycerides); blood pressure (systolic blood pressure and diastolic blood pressure); markers of NAFLD (intrahepatocellular lipids [IHCL], alanine aminotransferase [ALT], aspartate aminotransferase [AST]); uric acid; and markers of inflammation (CRP).
Data synthesis: The investigators will perform a network meta-analysis comparing all the interventions simultaneously. These interventions will include alternate day fasting, cyclical whole day fasting, time restricted feeding, continuous energy restriction, and ad libitum diet in a single analysis by combining both direct and indirect evidence across the selected network of studies. Separate pooled analyses will be conducted for each cardiometabolic risk factor using the random-effects network meta-analysis. Intrasitivity will be adjudged using incoherence. Global method of incoherence (design-by-treatment interaction) and inconsistency factors (disagreement between direct and indirect estimates) will be used to estimate incoherence. A-priori subgroup analyses (health status, age, control diet energy restriction, diet supervision, study design, follow-up, feeding control, randomization, energy balance, baseline body weight, funding source, and ROB) will be performed. Separate analysis will be performed in people with diabetes. Publication bias will be assessed if there are ≥10 comparisons. The overall certainty of the evidence for each outcome will be assessed with GRADE using the CINeMA approach.
Evidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant decision makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.
Significance: The proposed project will be the most comprehensive synthesis and evaluation of the totality of evidence on the role of intermittent fasting in cardiometabolic health. These findings will aid in strengthening current guidelines and improve health outcomes by informing shared clinical decision making between healthcare providers and patients and guiding future research.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Studies with intermittent fasting | – | Dietary Supplement: Intermittent FastingStudies with intermittent fasting strategies. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adults of all health statuses.
Key inclusion criteria (6 listed)
- Randomized controlled trials in humans
- Intermittent fasting intervention
- Continuous energy restriction, ad libitum diet, or other intermittent fasting diet as comparators
- Diet duration ≥1 weeks
- Data for at least one prespecified outcome
Key exclusion criteria (7 listed)
- Non-human studies
- Observational studies
- Children
- Multi-modal interventions
- Diet duration < 1 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intermittent FastingMethods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet. | Dietary supplement | Studies with intermittent fasting |
Primary outcome
Body weight
Time frame: Through study completion, up to 20 years
Body weight in kg
19 secondary outcomes
Adiposity - BMI
Time frame: Through study completion, up to 20 years
Adiposity - Waist circumference
Time frame: Through study completion, up to 20 years
Adiposity - Body fat
Time frame: Through study completion, up to 20 years
Glycemic control - HbA1c
Time frame: Through study completion, up to 20 years
Glycemic control - fasting plasma glucose (FPG)
Time frame: Through study completion, up to 20 years
Glycemic control - 2h plasma glucose (2h-PG)
Time frame: Through study completion, up to 20 years
Glycemic control - fasting plasma insulin (FPI)
Time frame: Through study completion, up to 20 years
Glycemic control - homeostasis model assessment of insulin resistance (HOMA-IR)
Time frame: Through study completion, up to 20 years
Established blood lipid targets - LDL-cholesterol (LDL-C)
Time frame: Through study completion, up to 20 years
Established blood lipid targets - non-HDL-cholesterol (non-HDL-C)
Time frame: Through study completion, up to 20 years
Established blood lipid targets - apolipoprotein B (apo B)
Time frame: Through study completion, up to 20 years
Established blood lipid targets - triglycerides
Time frame: Through study completion, up to 20 years
Established blood lipid targets - HDL-cholesterol (HDL-C)
Time frame: Through study completion, up to 20 years
Blood pressure - Systolic blood pressure (SBP)
Time frame: Through study completion
Blood pressure - diastolic blood pressure (DBP)
Time frame: Through study completion, up to 20 years
Markers of non-alcoholic fatty liver disease (NAFLD) - Intrahepatocellular lipids (IHCL)
Time frame: Through study completion, up to 20 years
Markers of non-alcoholic fatty liver disease (NAFLD) - alanine transaminase (ALT)
Time frame: Through study completion, up to 20 years
Uric acid
Time frame: Through study completion, up to 20 years
Markers of inflammation - CRP
Time frame: Through study completion, up to 20 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2022.
- Derived from this study: PubMed 40533200Semnani-Azad Z, Khan TA, Chiavaroli L, Chen V, Bhatt HA, Chen A, Chiang N, Oguntala J, Kabisch S, Lau DC, Wharton S, Sharma AM, Harris L, Leiter LA, Hill JO, Hu FB, Lean ME, Kahleova H, Rahelic D, Salas-Salvado J, Kendall CW, Sievenpiper JL. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. BMJ. 2025 Jun 18;389:e082007. doi: 10.1136/bmj-2024-082007.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity and PreDiabetes, run by University of Toronto at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body weight (time frame: Through study completion, up to 20 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05309057, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2022.